Can-Fite BioPharma’s Director of Business Development to Attend BioJapan Conference for Orphan Drug Development

Can-Fite BioPharma Ltd., a biotechnology company specializing in the development of small molecule drugs for oncology, inflammatory, and liver diseases, has announced that its Director of Business Development, Dr. Sari Fishman, will be attending the BioJapan Conference in Yokohama, Japan. The conference, which will take place from October 11-13, 2023, will focus on the development of orphan drugs.

During the conference, Dr. Fishman will conduct virtual one-on-one meetings with Japanese companies that specialize in the development of orphan drugs. Can-Fite recently signed an agreement with Fondazione Telethon for the co-development of Piclidenoson, a drug for the treatment of Lowe syndrome. This collaboration is based on breakthrough findings by Dr. Antonella De Matteis, which showed the efficacy of Piclidenoson in pre-clinical studies for treating Lowe syndrome.

The interest shown by Japanese companies in Can-Fite’s rare genetic disease indication is a positive development for the company. The conference will also provide an opportunity for Can-Fite to present its other developments to leading Japanese pharmaceutical companies.

Can-Fite BioPharma is an advanced clinical-stage drug development company with a platform technology designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory diseases. The company’s lead drug candidate, Piclidenoson, recently reported positive results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III trial. Can-Fite’s other drug candidates, Namodenoson and CF602, are being evaluated for the treatment of liver diseases and erectile dysfunction, respectively.

With an excellent safety profile and experience in over 1,600 patients in clinical studies to date, Can-Fite’s drug candidates show promise in addressing unmet medical needs. The company has also received Orphan Drug Designation and Fast Track Designation for certain indications, further highlighting the potential of its pipeline.

For more information about Can-Fite BioPharma and its drug development efforts, visit their website at www.can-fite.com.